A Case Study On The Financial Performance Of Y Pharmaceutical Company Under The Light Asset Operation Model

The pharmaceutical manufacturing industry is closely related to the national economy and the people’s livelihood.With the rapid rise of China’s economic development and the gradual improvement of people’s material needs,people’s medical treatment rates and health awareness have also increased,greatly promoting the development of the pharmaceutical industry.At the same time,China’s medical system continues to deepen reform,the improvement of the social medical insurance system,and the introduction of national innovation driven policies.Various policies and benefits support the development of major pharmaceutical enterprises,leading to increasingly fierce market competition in the pharmaceutical industry.In addition,many foreign pharmaceutical enterprises have entered China,making the domestic pharmaceutical market more competitive.In this context,if pharmaceutical companies want to achieve more long-term and stable development in the market,they should continuously explore and update their own operational models suitable for their own development.Therefore,many pharmaceutical manufacturing enterprises have broken the inherent traditional operation mode and opted for an asset light operation mode to complete enterprise transformation and upgrading.This article selects Y Pharmaceutical Company as the case study object to study and analyze the financial performance of Y Pharmaceutical Company under the implementation of asset light operation mode.Firstly,by summarizing relevant literature and conducting research on relevant theories,this paper summarizes the concepts and theories of asset light and financial performance,as well as the research background and significance,providing a theoretical basis for the full text of the study.Secondly,it summarizes the development and operation status of Y Pharmaceutical Company,and analyzes the reasons and paths for its transformation to asset light operation.Subsequently,the financial performance of Y Pharmaceutical Company was evaluated and analyzed using the financial indicator analysis method and EVA analysis method.Based on the analysis results,the potential problems of Y Pharmaceutical Company’s financial performance under the asset light operation mode were summarized.It was found that there were risks in the management of accounts receivable,the lack of effective control over the quality of outsourced products,the instability of enterprise brand value,and low investment in R&D and innovation in the company’s asset light operation.In view of this,this article proposes targeted countermeasures such as strengthening internal management,improving the accounts receivable system,improving outsourcing forms,improving product quality,strengthening brand building,enhancing brand influence,paying attention to research and development design,and improving the core competitiveness of enterprises.Enterprises need to continuously improve the asset light operation mode in practice,giving full play to its best advantages,to ensure that enterprises can obtain greater benefits by using the asset light operation mode.Finally,I hope that the research in this article can have a certain reference value for Y Pharmaceutical Company and enterprises in the same industry.